SFEBES2026 Poster Presentations Neuroendocrinology and Pituitary (40 abstracts)
CAM2029 octreotide subcutaneous depot maintains control of IGF-I and symptoms of acromegaly across a 4-week dosing interval and for intervals greater than 28 days: data from the ACROINNOVA 1 trial
Mônica R. Gadelha 1 , Robert D. Murray 2 , Harpal S. Randeva 3,4 , Tara Kearney 5 , Diego Ferone 6 , Maria Fleseriu 7 , Jacob Råstam 8 , Alberto M. Pedroncelli 8 , Fredrik Tiberg 8 & Beverly M. K. Biller 9
1Neuroendocrinology Research Center/Endocrinology Division, Medical School and Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 2Department of Endocrinology, St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; 3Warwick Medical School, University of Warwick, Coventry, United Kingdom; 4WISDEM, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom; 5Department of Endocrinology, Manchester Centre for Clinical Neurosciences, Salford Royal Foundation Trust, Manchester, United Kingdom; 6Endocrinology Unit, Department of Internal Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 7Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health and Science University, Portland, OR, USA; 8Camurus AB, Lund, Sweden; 9Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA, USA
Waning biochemical and symptom control has been reported in patients with acromegaly towards the end of dosing intervals with standard-of-care (SoC) injectable somatostatin receptor ligands. CAM2029 is a long-acting octreotide subcutaneous depot designed for monthly self-administration. In the 24-week (W), Phase 3 ACROINNOVA 1 trial (NCT04076462), CAM2029 (20 mg every 4W [±1W]) demonstrated superior biochemical control (insulin-like growth factor I [IGF-I] ≤ upper limit of normal [ULN; per age and sex]) vs placebo (72.2% vs 37.5%; P=0.0018) in patients controlled with SoC at screening. We report analyses of IGF-I and symptom control over a 4W dosing interval. The final CAM2029 dose was received at W20; the end of trial (EOT) was scheduled for W24. IGF-I levels and Acromegaly Index of Severity (AIS; key acromegaly symptoms evaluated by the clinician with the patient) scores were assessed at W20 before administration of CAM2029, W22 and W24/EOT (intervals ≤28 days). Some patients experienced delays in their planned W24/EOT visits, resulting in later assessments (intervals >28 days). Forty-two patients (87.5%) randomized to CAM2029 completed treatment. 45.2% (19/42) underwent W24/EOT assessment ≤28 days post-dose. Mean IGF-I/ULN values remained controlled across W20 (0.83), W22 (0.77) and W24/EOT (0.80). Mean AIS overall scores were stable from W20 (4.7) to W22 (4.2) and W24/EOT (3.6). 54.8% (23/42) of patients had dosing intervals of >28 days (maximum 42 days; mean 33.4 days). Mean IGF-I/ULN values were controlled across the >28-day dosing interval (0.81, 0.84 and 0.78 at W20, W22 and W24/EOT, respectively). CAM2029 also maintained stable mean AIS overall scores across W20 (4.3), W22 (4.3) and W24/EOT (4.7) in those with later assessments (>28 days). CAM2029 maintained stable biochemical and symptom control throughout the 4W dosing interval, including in patients whose intervals extended >28 days. These data reinforce CAM2029’s potential to address unmet needs among patients with acromegaly.
Volume 117
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2026 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more